Backed by Core Patents: Jingyue Bios R&D Strength Reaches New Heights with Technological Breakthrough in January 2025

In January 2025, Zhejiang Jingyue Biotechnology garnered widespread industry attention with its robust R&D capabilities, as a key breakthrough was achieved in the development technology of its core product, "Ningyi Qingyuan Buccal Tablets," highlighting the company's profound expertise in the field of medicine and food homology. This product was meticulously developed by a research team led by Professor Zhang Zhaotao from Wuhan University, who has over a decade of in-depth research on bioactive ingredients and has participated in multiple national-level key scientific research projects, boasting a solid theoretical foundation and rich practical experience.

Addressing health issues such as hyperuricemia and hyperlipidemia, the R&D team broke through traditional technical bottlenecks and innovatively combined the essence of natural lemon with specific probiotic strains to form a unique multi-effect formula. This R&D achievement has been granted an invention patent (Patent No.: ZL201410798707.1), building a solid intellectual property protection barrier. During production, 定向酶解 (directional enzymatic hydrolysis) and composite emulsification technologies are adopted to ensure efficient delivery of active ingredients, maximizing product efficacy.

Three months of pilot application data further validated the product's reliable efficacy: 94% of hyperuricemia users saw their uric acid levels return to normal, 87% of hyperlipidemia users experienced a significant reduction in triglycerides, and 79% of users reported noticeable improvements in skin glossiness. Leveraging top research resources such as Wuhan University's national-level virtual simulation experimental teaching center, Jingyue Bio has established an integrated industry-academia-research R&D system. In the future, the company will apply for no fewer than 2 invention patents annually to maintain a leading position in technological iteration.